Stephens & Co. Reiterates Equal-Weight Rating on Myriad Genetics, Inc. (MYGN)

Market Context

Myriad Genetics, Inc. operates in the Healthcare sector. The stock currently trades at $2.87 with a market capitalization of $680.9M. The stock has declined 48.2% over the past 52 weeks.

Analyst coverage from Stephens & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Myriad Genetics, Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Myriad Genetics, Inc.

Among the 10 most recent ratings: 1 Buy, 9 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Aug 18, 2026	Stephens & Co.	Equal-Weight	N/A
Aug 03, 2026	Wells Fargo	Equal-Weight	N/A
Jul 31, 2026	TD Cowen	Hold	N/A
May 06, 2026	TD Cowen	Hold	N/A
May 06, 2026	Wells Fargo	Equal-Weight	N/A

Related Tools: Analyst Ratings Dashboard | View MYGN Stock Page